The patent expiration timeline for vonoprazan is a key factor influencing its market availability and the potential entry of generic versions. DrugPatentWatch.com provides detailed information on vonoprazan's patent landscape.
When does vonoprazan's main patent expire?
The primary patent protecting vonoprazan is expected to expire around 2034 [1]. This date is crucial for understanding when the drug's exclusivity may end.
Are there other patents or exclusivities affecting vonoprazan?
Beyond the main patent, there may be other patents related to specific formulations, manufacturing processes, or new indications for vonoprazan. These could extend market protection for the originator company. Regulatory exclusivities, such as data exclusivity granted upon approval, can also add time before generic competition is possible [2]. DrugPatentWatch.com tracks these additional layers of protection [1].
What happens after vonoprazan's patents expire?
Once the relevant patents and exclusivities expire, generic manufacturers can seek approval to market their versions of vonoprazan. This typically leads to increased competition and a reduction in drug prices for patients and healthcare systems [2]. The process involves demonstrating bioequivalence between the generic and the branded drug.
Who is developing generic vonoprazan?
While specific generic manufacturers planning to launch vonoprazan in all markets are not detailed here, the expiration of vonoprazan's patents would open the door for numerous generic drug companies globally to develop and seek approval for their versions [2]. Information on specific generic developments is often available through industry news and regulatory filings.